# Propranolol on Post Stroke Immune Status and Infection

> **NCT05375240** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University General Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Stroke
- Cerebrovascular Disorders
- Ischemic Stroke
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Cardiovascular Diseases
- Propranolol
- Beta Blocker
- Molecular Mechanisms of Pharmacological Action
- Immunologic Factors
- Physiological Effects of Drugs

## Interventions

- **DRUG:** Propranolol
- **DRUG:** Ceftriaxone

## Key facts

- **NCT ID:** NCT05375240
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06
- **Primary completion:** 2024-06
- **Final completion:** 2024-06
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2022-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05375240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05375240, "Propranolol on Post Stroke Immune Status and Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05375240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*